Wojciech Jurczak

1999–2025 年に発表

144
論文数
20,218
被引用数
56
h 指数
126
i10 指数

被引用数

Wojciech Jurczak の年別被引用数2001 年: 被引用 1 件2002 年: 被引用 1 件2003 年: 被引用 2 件2004 年: 被引用 3 件2005 年: 被引用 2 件2006 年: 被引用 2 件2007 年: 被引用 1 件2008 年: 被引用 2 件2009 年: 被引用 4 件2010 年: 被引用 3 件2011 年: 被引用 7 件2012 年: 被引用 2 件2013 年: 被引用 13 件2014 年: 被引用 60 件2015 年: 被引用 73 件2016 年: 被引用 73 件2017 年: 被引用 146 件2018 年: 被引用 172 件2019 年: 被引用 533 件2020 年: 被引用 690 件2021 年: 被引用 908 件2022 年: 被引用 883 件2023 年: 被引用 785 件2024 年: 被引用 1,437 件2025 年: 被引用 798 件2026 年: 被引用 18 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,865 件、この内訳の 24.9%中国: 引用元論文 573 件、この内訳の 7.7%イギリス: 引用元論文 487 件、この内訳の 6.5%イタリア: 引用元論文 474 件、この内訳の 6.3%ドイツ: 引用元論文 466 件、この内訳の 6.2%フランス: 引用元論文 397 件、この内訳の 5.3%オーストラリア: 引用元論文 310 件、この内訳の 4.2%スペイン: 引用元論文 293 件、この内訳の 3.9%カナダ: 引用元論文 254 件、この内訳の 3.4%スイス: 引用元論文 202 件、この内訳の 2.7%オランダ: 引用元論文 200 件、この内訳の 2.7%日本: 引用元論文 150 件、この内訳の 2%
0%24.9%その他 24.2%

分野

  • Medicine80.7%
  • Biochemistry, Genetics and Molecular Biology14%
  • Immunology and Microbiology3.2%
  • Chemistry0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • Mathematics0.2%
  • その他0.9%

トピック

  • Lymphoma Diagnosis and Treatment17.8%
  • Chronic Lymphocytic Leukemia Research13.9%
  • CAR-T cell therapy research7.8%
  • Viral-associated cancers and disorders2.9%
  • Chronic Myeloid Leukemia Treatments2.4%
  • Cutaneous lymphoproliferative disorders research2.3%
  • その他52.9%

共著者

全論文

検索で開く
  1. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 523

  2. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 被引用: 843

  3. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 635

  4. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 457

  5. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 587

  6. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 被引用: 612

  7. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Hillmen - The Lancet Oncology 2022 被引用: 278

  8. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the PHOENIX investigators - Journal of Clinical Oncology 2019 被引用: 616

  9. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 519

  10. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amy S. Ruppert, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak - New England Journal of Medicine 2023 被引用: 217

  11. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 547

  12. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kristie A. Blum - New England Journal of Medicine 2013 被引用: 1,687

  13. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 被引用: 454

  14. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aileen Cohen, Jane Huang, Meletios Α. Dimopoulos - Blood 2020 被引用: 448

  15. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 764

  16. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2022 被引用: 200

  17. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski ほか 69 名 - The Lancet 2018 被引用: 726

  18. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2024 被引用: 139

  19. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 796

  20. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

    著者: , , , , , , , , , , , , , , , , , - Blood 2023 被引用: 119

  21. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 270

  22. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 362

  23. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 448

  24. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia

    著者: , , , , , , - British Journal of Haematology 2018 被引用: 217